Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Alexander W, Hauswirth"'
Autor:
Irina Sadovnik, Daniel Ivanov, Dubravka Smiljkovic, Gabriele Stefanzl, Lina Degenfeld-Schonburg, Susanne Herndlhofer, Gregor Eisenwort, Alexander W. Hauswirth, Thamer Sliwa, Felix Keil, Wolfgang R. Sperr, Peter Valent
Publikováno v:
Cells, Vol 12, Iss 1, p 3 (2022)
Basophilia is a crucial prognostic variable in Ph-chromosome-positive chronic myeloid leukemia (CML). The ectoenzyme CD203c is an activation-linked surface antigen that is expressed specifically on basophil-committed progenitor cells and mature basop
Externí odkaz:
https://doaj.org/article/cf50c9f3426b423a9d5166447b5e48b9
Autor:
Philipp B. Staber, Berend Snijder, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Niklas Zojer, Christoph C. Zielinski, Dominik Wolf, Cora Waldstein, Stefan Vogt, Katrina Vanura, Emiel van der Kouwe, Peter Valent, Renate Thalhammer, Ismet Srndic, Wolfgang R. Sperr, Cathrin Skrabs, Christian Sillaber, Edgar Selzer, Ilse Schwarzinger, Ann-Sofie Schmolke, Ana-Iris Schiefer, Julius Salamon, Reinhard Ruckser, Robin Ristl, Markus Raderer, Gerald W. Prager, Edit Porpaczy, Alexander Pichler, Michael Panny, Leopold Öhler, Katharina Ocko, Thomas Noesslinger, Peter Neumeister, Leonhard Müllauer, Katsuhiro Miura, Olaf Merkel, Elisabeth Menschel, Marius E. Mayerhoefer, Simone Lubowitzki, Trang Le, Stefan Kubicek, Gerhard Krajnik, Nikolaus Krall, Barbara Kiesewetter, Lukas Kenner, Lukas Kazianka, Ulrich Jaeger, Georg Hopfinger, Mir Alireza Hoda, Daniel Heintel, Tim Heinemann, Alexander W. Hauswirth, Bernd Lorenz Hartmann, Marcus Hacker, Wolfgang Gstöttner, Hildegard T. Greinix, Klaus Geissler, Alexander Gaiger, Maurizio Forte, Verena Felsleitner-Hauer, Ruth Exner, Harald Esterbauer, Martin Erl, Ruth Eichner, Sandra Eder, Michael Bergmann, Günther Bayer, Gregory I. Vladimer, Tea Pemovska, Christoph Kornauth
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9887042c05486a909c745cd96689d6c
https://doi.org/10.1158/2159-8290.c.6549464.v1
https://doi.org/10.1158/2159-8290.c.6549464.v1
Autor:
Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, Ismet Srndic
Publikováno v:
Cancer Discovery, 12 (2)
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ef6465faab2cb5917a550f8e3d5a11
https://doi.org/10.1158/2159-8290.cd-21-0538
https://doi.org/10.1158/2159-8290.cd-21-0538
Autor:
Ingrid Pabinger, Filippo Cacioppo, Paul Knöbl, Peter Quehenberger, Johannes Thaler, Alexander W. Hauswirth, Karoline V. Gleixner, Cihan Ay, Jürgen Grafeneder
Publikováno v:
Journal of Thrombosis and Haemostasis. 19:1819-1822
Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV-19 vaccine (AstraZeneca) have been reported. The term vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f11b9930460e15ca4a22dd947255c71
https://doi.org/10.1111/jth.15346
https://doi.org/10.1111/jth.15346
Autor:
Tina Künz, Alexander W. Hauswirth, Gabriele Hetzenauer, Jakob Rudzki, David Nachbaur, Normann Steiner
Publikováno v:
Cancers. 14(17)
Acute lymphoblastic leukemia (ALL) is a rare hematological malignancy characterized by proliferation and accumulation of premature lymphoid blasts. Depending on risk factors, the survival of acute lymphoblastic leukemia has significantly improved ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c6979d87411d309f94c7dd68ac58df4
https://pubmed.ncbi.nlm.nih.gov/36077822
https://pubmed.ncbi.nlm.nih.gov/36077822
Autor:
Tea Pemovska, Alexander Pichler, Leonhard Muellauer, Wolfgang R. Sperr, Trang Le, Ulrich Jaeger, Katrina Vanura, Christoph Kornauth, Nikolaus Krall, Giulio Superti-Furga, Renate Thalhammer, Peter Neumeister, Philipp B. Staber, Gregory I. Vladimer, Edit Porpaczy, Harald Esterbauer, Christoph C. Zielinski, Julius Salamon, Reinhard Ruckser, Katharina Ocko, Ilse Schwarzinger, Ruth Eichner, Markus Raderer, Ruth Exner, Michael Panny, Gerald W. Prager, Wolfgang Gstöttner, Verena Felsleitner-Hauer, Edgar Selzer, Lukas Kenner, Maurizio Forte, Marius E. Mayerhoefer, Ana-Iris Schiefer, Lukas Kazianka, Alexander Gaiger, Günther Bayer, Ann-Sofie Schmolke, Stefan Vogt, Cora Waldstein, Daniel Heintel, Berend Snijder, Marcus Hacker, Robin Ristl, Barbara Kiesewetter, Alexander W. Hauswirth, Mir Alireza Hoda, Katsuhiro Miura, Dominik Wolf, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Emiel van der Kouwe, Simone Lubowitzki, Elisabeth Menschel, Peter Valent, Hildegard Greinix, Sandra Eder, Olaf Merkel, Leopold Öhler, Michael Bergmann, Tim Heinemann, Ismet Srndic, Thomas Noesslinger
Publikováno v:
Blood. 136:2-4
Background: Aggressive hematological malignancies in relapsed/refractory setting bear a dire prognosis with low cure rates and short survival. Matching these patients to therapies is challenged by complexity due to spatial and temporal tumor evolutio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a7e822d529f8a6431b5e5c93b1ebe2
https://doi.org/10.1182/blood-2020-140831
https://doi.org/10.1182/blood-2020-140831
Autor:
Alexander W. Hauswirth, Cathrin Skrabs, Christian Schützinger, Markus Raderer, Andreas Chott, Peter Valent, Klaus Lechner, Ulrich Jäger
Publikováno v:
Haematologica, Vol 93, Iss 3 (2008)
Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin’s lymphomas and may complicate the treatment. We analyzed an original series from our institute as well as published cases of non-Hodgkin’s lymphomas (excluding
Externí odkaz:
https://doaj.org/article/472680ed514e43daa7bdf8ce18482f1c
Autor:
Alexander W. Hauswirth, Ulrich Jäger
Publikováno v:
Haematologica, Vol 93, Iss 1 (2008)
Externí odkaz:
https://doaj.org/article/3a745025c8474fd291e666551335ab95
Autor:
Irene Graf, Gerlinde Mitterbauer-Hohendanner, Wolfgang R. Sperr, Georg Greiner, Ilse Schwarzinger, Rodrig Marculescu, Peter Valent, Susanne Herndlhofer, Ulrich Jaeger, Alexander W. Hauswirth, Gabriele Stefanzl, Michael Kundi, Gregor Hoermann, Karoline V. Gleixner, Paul Knoebl, Renate Thalhammer
Publikováno v:
Blood. 138:3435-3435
Acute myeloid leukemia (AML) is a hematologic neoplasm resulting from abnormal proliferation and accumulation of clonal myeloid precursor cells. The course and prognosis of AML vary depending on the type of AML, karyotype, and molecular abnormalities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d782b16ce8875621597aaeed0e7a844
https://doi.org/10.1182/blood-2021-149526
https://doi.org/10.1182/blood-2021-149526
Autor:
Georg Hopfinger, Marie-Bernadette Aretin, Christoph Kornauth, Nicole Prutsch, Philipp B. Staber, Bernadette Hilgarth, Ulrich Jäger, Emiel van der Kouwe, Sinan Gültekin, Ingrid Simonitsch-Klupp, Stefan Kubicek, Lukas Kazianka, Peter Valent, Gregor Hoermann, Marius E. Mayerhoefer, Lukas Kenner, Alexander W. Hauswirth, Olaf Merkel, Richard Moriggl, Wolfgang R. Sperr, Bernd Boidol, Michael Panny
Publikováno v:
Blood. 130:2499-2503
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-lymphoid malignancy usually refractory to current treatment strategies and associated with short overall survival. By applying next-generation functional testing of primary patient-der
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10396821870c0d2a3fcb8be16a245941
https://doi.org/10.1182/blood-2017-05-785683
https://doi.org/10.1182/blood-2017-05-785683